# Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/schedules-controlled-substances-placement-schedule-i/ > **Published:** 2026-03-10T11:16:11-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:26:04-04:00 > **Clinical Summary:** Learn about the schedules of controlled substances placement for etodesnitazene, N-pyrrolidino etonitazene, and protonitazene in Schedule I by the DEA. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Regulations.gov PolicySafetyResearch Clinical Summary The DEA has placed three synthetic opioid analogs (etodesnitazene, N-pyrrolidino etonitazene, and protonitazene) into Schedule I, recognizing their high abuse potential and lack of accepted medical use. These compounds have emerged as drugs of abuse in illicit markets, often sold as heroin or fentanyl substitutes, and have been associated with overdose deaths and emergency department visits across multiple states. This scheduling action closes a regulatory gap that previously allowed these substances to circulate as uncontrolled “designer drugs” while authorities worked to classify them. For clinicians, this regulatory action reflects the evolving landscape of synthetic opioid threats in their communities and underscores the importance of staying informed about emerging substances that may present as conventional drugs of abuse. Patients presenting with opioid overdose or addiction should be screened for exposure to these novel compounds, as standard toxicology screens may not detect them and clinical management principles for synthetic opioid toxicity may differ. Clinicians should remain vigilant for unusual presentations of opioid-related harm in their populations and coordinate with [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) authorities regarding emerging drug threats in their regions. Clinical Perspective The DEA’s scheduling of three novel nitazene analogs reflects the rapid emergence of synthetic opioids in the illicit drug supply, compounds that have been associated with overdose deaths but lack established clinical use or safety data in human populations. Clinicians should recognize that nitazenes—which produce opioid-like effects and may respond partially to naloxone—represent a growing toxicological challenge, particularly in patients presenting with unexplained altered consciousness or respiratory depression in settings with high illicit fentanoid use. The lack of routine screening for these substances in standard toxicology panels creates a critical blind spot in emergency and acute care settings, making clinical recognition based on presentation and collateral history essential. Regulatory scheduling, while important for supply-side interventions, does not change the immediate clinical reality that affected patients require [supportive care](https://cedclinic.com/pediatric-oncology-supportive-care-cannabis-research-funding-iowa/), opioid antagonists, and careful monitoring regardless of the specific agent involved. Providers should maintain 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Etodesnitazene%2C+N-Pyrrolidino+etonitazene%2C+and+Prot...+%40drcaplan&url=https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2021-0031-0006) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2021-0031-0006) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Etodesnitazene%2C+N-Pyrrolidino+etonitazene%2C+and+Prot...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2021-0031-0006) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Daily Digest: Last 9 Hours: Stroke Risk From Recreational Drugs and DEA Scheduling Actions — March 08, 2026](https://cedclinic.com/daily-digest-last-9-hours-stroke-risk-from-recreational-drugs-and-dea-scheduling-actions-march-08-2026/) - [Firefighters are a step closer to being able to use medical cannabis – WMAR](https://cedclinic.com/medical-cannabis-firefighters-access-update/) - [Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds](https://cedclinic.com/cbd-cbg-fatty-liver-disease-research/) 📰 Source: [https://www.regulations.gov/document/DEA-2021-0031-0006](https://www.regulations.gov/document/DEA-2021-0031-0006) Further Reading Evidence Watch[`Cannabinoid Clinical Trials: CBD Cortical Excitability Study`](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Research Digest[Daily Digest 2026-03-07](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I](https://cedclinic.com/synthetic-opioids-schedule-i-placement-butonitazene-flunitazene/) Explore the DEA's scheduling of other synthetic opioids related to nitazenes and their regulatory impact. [Read More](https://cedclinic.com/synthetic-opioids-schedule-i-placement-butonitazene-flunitazene/) [Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I](https://cedclinic.com/dea-temporary-placement-schedule-i-n-desethyl-isotonitazene/) Review the temporary scheduling actions for related synthetic opioids and their clinical significance. [Learn More](https://cedclinic.com/dea-temporary-placement-schedule-i-n-desethyl-isotonitazene/) [Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-placement/) Understand the broader context of synthetic cannabinoid scheduling alongside opioid analogs. [Explore Now](https://cedclinic.com/synthetic-cannabinoids-schedule-i-placement/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).